ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag pharma developmental biology genetics genomics

Cropped view of senior man playing with puzzles
A Rare Genetic Mutation Protects Against Alzheimer's Disease
Hannah Thomasy, PhD, Drug Discovery News | Sep 17, 2023 | 4 min read
Data from a highly resilient individual guided researchers to new potential therapeutic targets.
On the left is a normally developing mouse embryo, on the right is a slightly larger mouse embryo that also contains horse cells that glow green.
Chimera research opens new doors to understanding and treating disease
Hannah Thomasy, PhD, Drug Discovery News | Aug 9, 2023 | 10 min read
Animals with human cells could provide donor organs or help us understand neuropsychiatric disorders.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Advances in the functional characterization of newly discovered microproteins hint at their diverse roles  in health and disease
The Dark Matter of the Human Proteome
Annie Rathore | Apr 1, 2019 | 10 min read
Advances in the functional characterization of newly discovered microproteins hint at diverse roles in health and disease.
Single Nucleotide Polymorphisms: Big Pharma Hedges its Bets
Eugene Russo | Jul 18, 1999 | 7 min read
SNP CENTRAL: A genetics researcher takes to the bench at the Wellcome Trust's Sanger Centre in Cambridge, England. The sequencing center and its London sponsor provided key leadership in the SNP Consortium, a public-private venture to find and map 300,000 single nucleotide polymorphisms. The Wellcome Trust helped entice 10 pharmaceutical firms to join the consortium by putting up $14 million of the project's estimated $45 million price tag. The Sanger Centre will provide much of the radiation h
Recent Trials for Fragile X Syndrome Offer Hope
Randi Hagerman | Sep 1, 2019 | 10+ min read
Despite a solid understanding of the biological basis of fragile X syndrome, researchers have struggled to develop effective treatments.
Top 10 Innovations 2021
2021 Top 10 Innovations
The Scientist | Dec 1, 2021 | 10+ min read
The COVID-19 pandemic is still with us. Biomedical innovation has rallied to address that pressing concern while continuing to tackle broader research challenges.
A Flood in Genomics
Brendan Maher | Nov 25, 2001 | 9 min read
Nine months have passed since draft sequences of the human genome were first published.1,2 One human gestation period later, the genome, as deciphered by the International Human Genome Sequencing Consortium, still screams toward its projected Spring 2003 finish date. "The trajectory we're on for meeting that goal is precisely on target," assures Francis Collins, director, National Human Genome Research Institute (NHGRI) and spokesperson for the largest public biological science project in histor
The Genetics of Society
Claire Asher and Seirian Sumner | Jan 1, 2015 | 10 min read
Researchers aim to unravel the molecular mechanisms by which a single genotype gives rise to diverse castes in eusocial organisms.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard

Run a Search

ADVERTISEMENT